Evidence map›Paper›PMID 40592585›Full record

ArticleThe British journal of ophthalmology2025

Differentiating treatment episodes from gaps in eyes with diabetic macular oedema.

Yohei Hashimoto, Adrian Robert Hunt, Rufino Silva, Antonella Witmer, Wajiha Jurdi Kheir, Francesco Viola, Maite Arrazola, Mohamed Moghazy Mahgoub, Andreas Pollreisz, Zanne Harvey and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yohei HashimotoSave Sight Institute, The University of Sydney, Sydney, New South Wales, Australia yohei.hashimoto@sydney.edu.au.ORCID http://orcid.org/0000-0002-7944-6923
Adrian Robert HuntSave Sight Institute, The University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-6261-4679
Rufino SilvaDepartment of Ophthalmology, Hospital of the University of Coimbra, Coimbra, Portugal.ORCID http://orcid.org/0000-0001-8676-0833
Antonella WitmerDepartment of Ophthalmology, OLVG Hospital, Amsterdam, The Netherlands.
Wajiha Jurdi KheirOpthalmology, American University of Beirut Medical Center, Beirut, Lebanon.ORCID http://orcid.org/0000-0002-4063-3860
Francesco ViolaOphthalmology, Universita degli Studi di Milano, Milano, Italy.ORCID http://orcid.org/0000-0003-1208-913X
Maite ArrazolaDepartment of Ophthalmology, University Hospital of Basurto, Bilbao, Spain.
Mohamed Moghazy MahgoubAin Shams University, Cairo, Egypt.
Andreas PollreiszDepartment of Ophthalmology, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-3902-239X
Zanne HarveyEyes Wide Bay, Hervey Bay, Queensland, Australia.
Daniel BarthelmesUniversitatsspital Zurich Augenklinik und Poliklinik, Zurich, Switzerland.
Mark C GilliesSave Sight Institute, The University of Sydney, Sydney, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of diabetic macular oedema (DMO) likely involves a series of treatment episodes separated by gaps during which no vascular endothelial growth factor inhibitor injections are delivered. Our aim is to differentiate the episodes and gaps with the isolation forests algorithm using the Fight Retinal Blindness! registry. We analysed 11 786 injection intervals (12 803 injections) and found that the period between adjacent injections≥38 weeks (95% CI 34 to 43 weeks) apart could be regarded as a treatment gap. The results will allow treatment episodes to be isolated so that the treatment patterns of DMO can be characterised more accurately.

Indexed as

Angiogenesis InhibitorsDiabetic RetinopathyMacular EdemaRanibizumabAgedAlgorithmsFemaleHumansIntravitreal InjectionsMaleMiddle AgedRegistriesTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AVEGFA protein, humanMaculaTreatment Medical

Identifiers

PMID40592585
PMCPMC12573354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.